Pharma and Medtech Revenue Rankings: The 2025 Shifts and the 2026 Outlook

The competitive hierarchy in both pharmaceuticals and medtech is shifting, with new leaders emerging from the growth in metabolic disease treatments and strategic corporate moves. In the blockbuster drug race, Eli Lilly has overtaken its Danish rival Novo Nordisk. Last year, Lilly's GLP-1 drugs generated DKK 231bn in sales, edging out Novo Nordisk's leading drug by DKK 3bn. This marks a pivotal moment, as Novo had held a significant head start in both diabetes and weight-loss markets.

The medtech sector's established order is also set for a change. As of 2024, the top two companies by revenue were Medtronic and Johnson & Johnson MedTech, with sales of $33.54 billion and $31.90 billion respectively. However, a structural shift is poised to flip this ranking next year. Medtronic is planning to separate its $2.8-billion-a-year diabetes tech business, a move that will shrink its core medtech revenue. This strategic divestiture creates an opening for Johnson & Johnson MedTech to surpass it, setting the stage for a new #1 in the industry.

The bottom line is a landscape defined by both product momentum and corporate restructuring. Lilly's sales surge demonstrates the power of first-mover advantage being challenged, while the impending Medtronic-J&J reshuffle shows how corporate strategy can directly alter the competitive map.

The Growth Engines: GLP-1 Dynamics and Medtech Resilience

The story of 2025 is one of a market in motion, driven by a clear shift in pharmaceutical dominance and a resilient, expanding medtech sector. In the GLP-1 arena, the race has turned decisively. While Novo Nordisk's flagship drugs Wegovy and Ozempic still command massive sales, their growth is decelerating. In its third-quarter report, the company lowered its full-year sales forecast for the third time this year, a stark signal of market share erosion. Its obesity drug sales grew just 18% year-over-year, down from 67% in the prior quarter, while its diabetes medicine saw a mere 3% increase. By contrast, Eli Lilly's Q3 sales for its GLP-1 drugs Zepbound and Mounjaro grew at triple-digit rates, capturing a commanding lead in the US market.

This dynamic sets up a new battleground. Novo Nordisk is banking on its upcoming Wegovy pill, which it expects to launch early next year, as a potential equalizer. The race is now on to win the next generation of weight-loss treatments, with Lilly also planning to file for approval of its oral candidate later this year. The outcome will hinge on who can first convert the convenience of a pill into a broad patient base.

Meanwhile, the medtech sector is demonstrating remarkable stability. The industry is projected to reach $584 billion in revenue in 2025, growing at a steady 6-7% pace for the seventh consecutive year. This consistent expansion underscores the sector's fundamental resilience. Abbott is a standout performer, with its medtech business revenue jumping 13.4% sequentially to $18.9 billion in Q2 2025. The company's strength is broad-based, spanning diabetes care and heart treatments, highlighting how diversified portfolios can navigate economic uncertainty.

The bottom line is a dual narrative. On one side, the pharmaceutical growth engine is being redefined by a single class of drugs, with the leadership baton now in Lilly's hands. On the other, medtech is proving to be a reliable, high-volume engine, powered by innovation and a shift in care delivery. For investors, the setup is clear: the next phase of pharma growth will be fought over oral GLP-1s, while medtech's steady climb offers a counterbalance of predictable expansion.

Financial Impact and Strategic Implications

The revenue shifts of 2025 are translating directly into financial market valuations, revealing a clear divergence in investor confidence. In medtech, the premium for growth is evident. The median trading revenue multiple for deals in the sector rose to 4.2x in Q4 2025, up from 3.5x a year ago. This expansion signals that buyers are willing to pay more for companies with demonstrable, consistent expansion, a trend supported by the industry's steady 6-7% growth trajectory and a surge in deal value to a decade-high $97.6 billion.

The pharma picture is more complex and reveals a market pricing in long-term uncertainty. Pfizer exemplifies this dynamic. Despite maintaining a stable revenue base of $63.63 billion in FY2024, its stock has tumbled more than a quarter over the past five years. This disconnect underscores how the market is discounting the future, likely factoring in the looming patent cliff for Keytruda and the broader challenges of post-pandemic normalization.

This sets up a stark contrast for investors. The financial profile of a company like Abbott, which posted sequential growth of 13.4% to $18.9 billion in Q2 2025, aligns with the premium being paid in the medtech market. Similarly, Eli Lilly's commanding lead in the GLP-1 race suggests a lower-risk, higher-multiple future compared to peers facing patent expirations. The strategic implication is that growth must be both current and visible to command a valuation multiple. For now, the market is rewarding proven expansion in medtech and the clear dominance of a new drug class, while it remains skeptical of established pharma giants navigating a period of structural change.

Catalysts and Watchpoints for 2026

The structural shifts of 2025 set the stage for a decisive 2026. For medtech, the immediate watchpoint is the second-quarter earnings report, which will test the sector's resilience against persistent headwinds. The industry's steady 6-7% growth trajectory is under pressure from inflation and trade uncertainty, as seen in Boston Scientific's reported concerns about US tariffs. Investors must scrutinize Q2 results for signs of margin compression or strategic pullbacks, which would signal that the sector's premium valuation, now trading at a median multiple of 4.2x revenue, may be vulnerable.

For pharma, the timeline is longer but no less critical. The looming patent expiration for Merck's Keytruda in 2028 represents the single biggest revenue risk for the industry's current leader. The company's FY2024 sales of $29.5 billion for the drug underscore the scale of the challenge. The key metric to watch is the progress of Merck's pipeline to broaden its portfolio, a move essential for maintaining its dominance. Similarly, Pfizer's ability to stabilize its stock after a more than 25% tumble over five years will hinge on its non-COVID franchises and pipeline execution, not just its current $63.63 billion revenue base.

Finally, the financial architecture of the sector is being rewritten by mega-deals. The $18.3 billion acquisition of Hologic by Blackstone and TPG is a landmark transaction that will be a major focus for integration success. Its performance will provide a critical case study on whether such large-scale capital deployments create value or represent overpayment in a market where deal value has surged to a decade-high. The outcome will shape M&A sentiment across both medtech and pharma for the remainder of the decade.